The "try and fail" language is flawed when weight loss is used as the primary measure of success with lifestyle interventions ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

The analysis found that while the amount of weight regain varies by drug, there is a consistent pattern of rapid weight ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Curious about the viral “Japanese Mounjaro” drink? Learn what it is, what it’s made of, and whether it can actually support ...

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

A new study has found that a diabetes medicine called tirzepatide can help people lower their blood sugar and lose weight ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...